Skip to main content
. 2013 Jan-Feb;39(1):5–15. doi: 10.1590/S1806-37132013000100002

Table 2. Pre- and post-doxycycline functional parameters, matrix metalloproteinase levels, VEGF-D levels, and Medical Outcomes Study 36-item Short-form Health Survey scores in the 13 lymphangioleiomyomatosis patients allocated to the doxycycline-responder groupa on the basis of their response to doxycycline (as determined by the variation in FEV1). b .

Variable Doxy-R group p
Pre-doxycycline Post-doxycycline
Pulmonary function test
FVC, L 3.0 ± 0.3 3.2 ± 0.3 0.023
FVC, % of predicted 90 ± 13 95 ± 12 0.026
FEV1, L 2.31 ± 0.40 2.40 ± 0.40 0.003
FEV1, % of predicted 84 ± 14 86 ± 14 0.002
FEV1/FVC ratio 0.77 ± 0.10 0.76 ± 0.10 0.173
TLC, L 4.6 ± 0.5 4.8 ± 0.6 0.310
TLC, % of predicted 98 ± 13 101 ± 15 0.327
RV, L 1.6 ± 0.5 1.6 ± 0.6 0.956
RV, % of predicted 117 ± 43 118 ± 47 0.940
RV/TLC ratio 0.34 ± 0.08 0.33 ± 0.08 0.640
DLCO, mL/min/mmHg 18.5 ± 6.0 18.0 ± 5.0 0.514
DLCO, % of predicted 72 ± 20 70 ± 18 0.448
Six-minute walk test
Distance, m 515 ± 66 523 ± 52 0.633
Minimum SpO2, % c 94 (93-95) 94 (91-95) 0.500
Biomarkers c
Serum MMP-9, ng/mL 837 (716-1,033) 1,103 (773-1,237) 0.328
Urinary MMP-9, pg/mL 8,905 (5,607-21,829) 6,735 (674-8,983) 0.050
Serum MMP-2, pg/mL 0 (0-182) 0 (0-40) 0.144
VEGF-D, pg/mL 413 (277-2,113) 328 (257-2,008) 0.374
SF-36 domains c
Physical functioning 75 (65-85) 80 (75-95) 0.281
Role-physical 50 (50-50) 100 (50-100) 0.020
Bodily pain 57.5 (55-90) 70 (55-77.5) 1.000
General health 80 (45-90) 75 (70-85) 0.412
Vitality 70 (45-90) 70 (70-85) 0.428
Role-emotional 33 (33-100) 100 (33-100) 0.158
Mental health 68 (40-84) 76 (52-88) 0.051
Social functioning 75.0 (50.0-88.5) 87.5 (62.5-100) 0.040

Doxy-R group: : doxycycline-responder group; minimum SpO2: minimum SpO2 sustained for 10 s;

MMP

: matrix metalloproteinase;

SF-36: : Medical Outcomes Study 36-item Short-form Health Survey.

a

Group of patients who responded to treatment with doxycycline, as evidenced by increased or stable FEV1 at doxycycline treatment month 12 in comparison with FEV1 at baseline.

b

Values expressed as mean ± SD, except where otherwise indicated.

c

Values expressed as median (interquartile range).